Safety and immunogenicity of an MF59® -adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

Highlights ► Two doses of MF59-H5N1 vaccine were well tolerated. ► Two doses of MF59-H5N1 vaccine induced adequate levels of seroprotection against homologous and cross-clade A/H5N1 virus. ► These data support the suitability of MF59-adjuvanted A/H5N1 vaccine for pre-pandemic use in adults and the e...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 30; no. 7; pp. 1388 - 1396
Main Authors: Vesikari, Timo, Forstén, Aino, Herbinger, Karl-Heinz, Cioppa, Giovanni Della, Beygo, Jenny, Borkowski, Astrid, Groth, Nicola, Bennati, Mariaviviana, von Sonnenburg, Frank
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 08-02-2012
Elsevier Limited
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► Two doses of MF59-H5N1 vaccine were well tolerated. ► Two doses of MF59-H5N1 vaccine induced adequate levels of seroprotection against homologous and cross-clade A/H5N1 virus. ► These data support the suitability of MF59-adjuvanted A/H5N1 vaccine for pre-pandemic use in adults and the elderly.
Bibliography:http://dx.doi.org/10.1016/j.vaccine.2011.12.009
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.12.009